07 marzo 2008
NeuroPharma . El NP-61 es capaz de Revertir el deficit Cognitivo y detener la formacion de Placas Amiloideas en el Cerebro . (Alzheimer).
Neurodegener Dis. 2008 . Epub 2008 Mar 6.
Potent beta-Amyloid Modulators.
García-Palomero E, Muñoz P, Usan P, Garcia P, Delgado E, De Austria C, Valenzuela R, Rubio L, Medina M, Martínez A.
Neuropharma SA, Madrid, Spain.
Currently, the potential to interfere with the pathology of beta-amyloid targeting a well-known drugable enzyme, the acetylcholinesterase (AChE), is opened. Peripheral or dual binding site inhibitors of AChE may simultaneously alleviate the cognitive and behavioral deficits in Alzheimer's disease (AD) patients and, more importantly, act as disease-modifying agents delaying amyloid plaque formation. As part of a rational drug design program directed to find dual binding site AChE inhibitors, several families of compounds have been synthesized as potent AChE inhibitors. From these series, several drug candidates were selected based on their potent and selective inhibition of AChE (subnanomolar activity) and their interference with the beta-amyloid aggregation in vitro (IC(50) in the low micromolar range). First in vivo data confirm our initial hypothesis. Oral treatment with NP-61 for 3 months is able to reverse the cognitive impairment (Morris water maze test) and to reduce plaque load in the brains of human amyloid precursor protein transgenic mice (Swedish mutation). These results suggest that NP-61, a potent beta-amyloid modulator, is able to reverse the AD-like neurodegenerative phenotype in transgenic mice, indicating a promising disease-modifying agent for clinical application. Copyright (c) 2008 S. Karger AG, Basel.
Potent beta-Amyloid Modulators.
García-Palomero E, Muñoz P, Usan P, Garcia P, Delgado E, De Austria C, Valenzuela R, Rubio L, Medina M, Martínez A.
Neuropharma SA, Madrid, Spain.
Currently, the potential to interfere with the pathology of beta-amyloid targeting a well-known drugable enzyme, the acetylcholinesterase (AChE), is opened. Peripheral or dual binding site inhibitors of AChE may simultaneously alleviate the cognitive and behavioral deficits in Alzheimer's disease (AD) patients and, more importantly, act as disease-modifying agents delaying amyloid plaque formation. As part of a rational drug design program directed to find dual binding site AChE inhibitors, several families of compounds have been synthesized as potent AChE inhibitors. From these series, several drug candidates were selected based on their potent and selective inhibition of AChE (subnanomolar activity) and their interference with the beta-amyloid aggregation in vitro (IC(50) in the low micromolar range). First in vivo data confirm our initial hypothesis. Oral treatment with NP-61 for 3 months is able to reverse the cognitive impairment (Morris water maze test) and to reduce plaque load in the brains of human amyloid precursor protein transgenic mice (Swedish mutation). These results suggest that NP-61, a potent beta-amyloid modulator, is able to reverse the AD-like neurodegenerative phenotype in transgenic mice, indicating a promising disease-modifying agent for clinical application. Copyright (c) 2008 S. Karger AG, Basel.
Prensa Española repite los titulares ,sobre la salida de NeuroPharma a bolsa en el 2009 , de hace un mes .
Hoy 7 Marzo 2008 :
Neuropharma, filial de Zeltia, retrasa hasta 2009 su salida a Bolsa .
http://www.cincodias.com/articulo/empresas/Neuropharma/filial/Zeltia/retrasa/2009/salida/Bolsa/cdsemp/20080306cdscdsemp_18/Tes/
10 Febrero 2008 :
Zeltia aplaza la salida a Bolsa de Neuropharma hasta 2009 por la incertidumbre en los mercados .
http://www.cincodias.com/articulo/empresas/Zeltia/aplaza/salida/Bolsa/Neuropharma/incertidumbre/mercados/cdssec/20080210cdscdsemp_3/Tes/
....Por suerte estaban los periodistas Venezolanos que Si prestaron atencion a las declaraciones del Sr . Fernadez Sousa , de lo contrario no nos hubieramos enterado de nada ....:
http://ve.invertia.com/noticias/noticia.aspx?idNoticia=200803061457_RTI_1204815478nL06897291&idtel=
Neuropharma, filial de Zeltia, retrasa hasta 2009 su salida a Bolsa .
http://www.cincodias.com/articulo/empresas/Neuropharma/filial/Zeltia/retrasa/2009/salida/Bolsa/cdsemp/20080306cdscdsemp_18/Tes/
10 Febrero 2008 :
Zeltia aplaza la salida a Bolsa de Neuropharma hasta 2009 por la incertidumbre en los mercados .
http://www.cincodias.com/articulo/empresas/Zeltia/aplaza/salida/Bolsa/Neuropharma/incertidumbre/mercados/cdssec/20080210cdscdsemp_3/Tes/
....Por suerte estaban los periodistas Venezolanos que Si prestaron atencion a las declaraciones del Sr . Fernadez Sousa , de lo contrario no nos hubieramos enterado de nada ....:
http://ve.invertia.com/noticias/noticia.aspx?idNoticia=200803061457_RTI_1204815478nL06897291&idtel=
Suscribirse a:
Entradas (Atom)